Skip to main content
Premium Trial:

Request an Annual Quote

ImmunArray Lands $10M in Private Financing

NEW YORK (GenomeWeb) – Molecular diagnostics firm ImmunArray announced that it has received a $10 million Series B investment from private investment firm Exigent Capital.

Other details of the financing were not disclosed.

The firm, which is based in Israel and Virginia, markets blood-based tests based on its iChip antibody-detecting microarray technology. So far, it has developed a six-biomarker panel for ruling out systemic lupus erythematosus and is developing tests for traumatic brain injury and immuno-oncology. The iChip platform can print proteins and peptides, short sequences of nucleotides and DNA, as well as cell surface receptors, cytokines, chemokines, and even lipid or carbohydrate-based molecules.

The funding will help the firm "accelerate and expand our commercial infrastructure, widen our reach into lupus-related products, and broaden our work into other autoimmune diseases," said CEO Donna Edmonds in a statement, adding that the money would help the firm move toward commercializing its brain injury tests.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.